Vertex shares soar in 2017, and the best may be yet to come

Vertex Pharmaceuticals has been the top-performing stock in the S&P 500 so far this year, and further gains could be on the horizon. Shares of Boston-based Vertex (Nasdaq: VRTX), which makes cystic fibrosis drugs, have increased around 70 percent since the beginning of the year. That marks the biggest gain of any company on the S&P 500 during that period. (That fact was pointed out by the Wall Street Journal on Wednesday.) The jump can be attributed in part to the company’s announcement in late…
Source: bizjournals.com Health Care:Physician Practices headlines - Category: American Health Authors: Source Type: news